160 related articles for article (PubMed ID: 31700875)
1. Risk of second primary malignancy after non-small cell lung cancer: a competing risk nomogram based on the SEER database.
Zhou H; Shen J; Zhang Y; Huang Y; Fang W; Yang Y; Hong S; Liu J; Xian W; Zhang Z; Ma Y; Zhou T; Zhao H; Zhang L
Ann Transl Med; 2019 Sep; 7(18):439. PubMed ID: 31700875
[TBL] [Abstract][Full Text] [Related]
2. Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis.
Jia H; Li Q; Yuan J; Sun X; Wu Z
Oncologist; 2020 Apr; 25(4):e644-e650. PubMed ID: 31943509
[TBL] [Abstract][Full Text] [Related]
3. The risk and prognosis of secondary primary malignancy in lung cancer: a population-based study.
Hong J; Wei R; Nie C; Leonteva A; Han X; Du X; Wang J; Zhu L; Tian W; Zhou H
Future Oncol; 2021 Nov; 17(33):4497-4509. PubMed ID: 34402680
[TBL] [Abstract][Full Text] [Related]
4. Risk-based screening for second primary extrapulmonary malignancies in stage I lung cancer patients: A study based on SEER database.
Wang T; Zhou J; Zheng Q; Wu D; Lu T; Lin M; Pu Q; Mei J; Liu L
Lung Cancer; 2023 Jun; 180():107218. PubMed ID: 37146472
[TBL] [Abstract][Full Text] [Related]
5. Nomogram to Predict Cause-Specific Mortality in Patients With Surgically Resected Stage I Non-Small-Cell Lung Cancer: A Competing Risk Analysis.
Zhou H; Zhang Y; Qiu Z; Chen G; Hong S; Chen X; Zhang Z; Huang Y; Zhang L
Clin Lung Cancer; 2018 Mar; 19(2):e195-e203. PubMed ID: 29153966
[TBL] [Abstract][Full Text] [Related]
6. A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma.
Wu X; Yu W; Petersen RH; Sheng H; Wang Y; Lv W; Hu J
BMC Cancer; 2020 May; 20(1):429. PubMed ID: 32416716
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis.
Huang H; Li Z; Huang Z; Huang L; Liu W; Liu G; Mo Y
Front Oncol; 2023; 13():1076997. PubMed ID: 37152061
[TBL] [Abstract][Full Text] [Related]
8. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study.
Wang W
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138756
[TBL] [Abstract][Full Text] [Related]
9. Second Primary Malignancies in Patients With Hepatocellular Carcinoma: A Population-Based Analysis.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
Front Oncol; 2021; 11():713637. PubMed ID: 34497765
[TBL] [Abstract][Full Text] [Related]
10. Risk Prediction of Second Primary Malignancies in Primary Early-Stage Ovarian Cancer Survivors: A SEER-Based National Population-Based Cohort Study.
Xu J; Huang C; Wu Z; Xu H; Li J; Chen Y; Wang C; Zhu J; Qin G; Zheng X; Yu Y
Front Oncol; 2022; 12():875489. PubMed ID: 35664751
[TBL] [Abstract][Full Text] [Related]
11. Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study.
Lin X; Lin X; Li Y; Zhang Y; Lin J; Zhang G
Int J Gen Med; 2021; 14():8775-8784. PubMed ID: 34853531
[TBL] [Abstract][Full Text] [Related]
12. Analysis of chemotherapy effect on the second primary malignancy for head and neck cancer patients by a nomogram based on SEER database.
Li X; Guo K; Feng Y; Guo Y
Cancer Med; 2020 Nov; 9(21):8029-8042. PubMed ID: 32931661
[TBL] [Abstract][Full Text] [Related]
13. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; RodrÃguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
14. Standardized Incidence Rate, Risk and Survival Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-Control Study.
Wang Z; Yin Y; Wang J; Zhu Y; Li X; Zeng X
Front Oncol; 2021; 11():716741. PubMed ID: 34395291
[TBL] [Abstract][Full Text] [Related]
15. Second primary malignancy in patients with cholangiocarcinoma: a population-based study.
Zhuang L; Yan X; Meng Z
Cancer Manag Res; 2019; 11():1969-1983. PubMed ID: 30881122
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.
Liang Z; Zhang E; Duan L; Weygant N; An G; Hu B; Yao J
Technol Cancer Res Treat; 2022; 21():15330338211068960. PubMed ID: 35179409
[No Abstract] [Full Text] [Related]
17. Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018.
Wang J; Lv C; Zhou M; Xu JY; Chen B; Wan Y
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230842
[TBL] [Abstract][Full Text] [Related]
18. Competing-risk nomogram for predicting survival in patients with advanced (stage III/IV) gallbladder cancer: A SEER population-based study.
Wang J; Yang Y; Pan J; Qiu Y; Shen S; Wang W
Jpn J Clin Oncol; 2022 Apr; 52(4):353-361. PubMed ID: 35137118
[TBL] [Abstract][Full Text] [Related]
19. Risk prediction of second primary malignancies after gynecological malignant neoplasms resection with and without radiation therapy: a population-based surveillance, epidemiology, and end results (SEER) analysis.
Wang J; Zhang C; Xiang Y; Han B; Cheng Y; Tong Y; Yan D
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12703-12711. PubMed ID: 37452852
[TBL] [Abstract][Full Text] [Related]
20. Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis.
Li J; Zheng Q; Zhao X; Zhao J; An T; Wu M; Wang Y; Zhuo M; Zhong J; Yang X; Jia B; Chen H; Dong Z; Wang J; Chi Y; Zhai X; Wang Z
BMC Cancer; 2020 Aug; 20(1):793. PubMed ID: 32838776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
